ClinicalTrials.gg
Not yet recruitingNCT06741098Updated Dec 18, 2024

A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)

A Phase 1/2 interventional study of NCR100 and 0.9% Normal saline in Knee Osteoarthritis, sponsored by Nuwacell Biotechnologies Co., Ltd.. Not yet recruiting. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Nuwacell Biotechnologies Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It contains two parts dose-escalating, and blind random study in adult KOA subjects.

Read the detailed description

Knee osteoarthritis(KOA) is a kind of degenerative joint disease characterized by chronic inflammation loss of articular cartilage and subchondral bone remodeling.In China, the estimated number of patients diagnosed with KOA reached 37.35millon. The aim of this sudy is to evaluate the safety tolerability and efficacy of human pluripotent stem cell derived mesenchymal stromal cells (NCR100) injection in the treatment of subjects with knee osteoarthritis.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • KOA
  • Mesenchymal Stromal Cells
03

In context

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

This study's planned enrollment of 162 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Nuwacell Biotechnologies Co., Ltd. is the lead sponsor of 10 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who understand and voluntarily sign the Form(ICF) before the enrolment;
  • Age: 40-65 years old, both genders;
  • Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria;
  • Subjects with KOA who have persistent pain for more than six months
  • Kellgren-Lawrence grade: II-III

Exclusion criteria

Exclusion Criteria:

  • Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip/ankle joint disease requiring medical intervention;
  • Suffering from other diseases that impair knee function or joints;
  • Have received stem cell therapy;
  • Have knee injury history;
  • Experienced knee surgery, or plan to undergo knee surgery;
  • Received analgesics to relieve pain before Medicinal Product(IMP) injections;
  • Have used traditional Chinese medicine to treat KOA within 4 weeks;
  • Have used intra-articular injection of drugs to treat KOA within 12 weeks;
  • Received glucosamine,chondroitin sulfate, or diacetate therapy before investigational drug intervention within 12 weeks;
  • Subjects with acute phase of knee osteoarthritis;
  • Severe deformity of the knee;
  • Known or suspected allergy or a history of allergies;
  • Abnormal results of laboratory examination as follows: Hepatic Insufficiency (>2xULN or Aspartate aminotransferase [ast]>2xULN) renal dysfunction ( rate ≤60ml/min or blood urea nitrogen(BUN) > 2× ), Coagulation Defects ( > 1.5) or severe hematological diseases (Grade 3 or above anemia [ \< 8 g/dL], Grade 2 or above thrombocytopenia count(PLT) \< 75×10\^9/L) ;
  • ≥30kg/m\^2
  • Severe systemic infection or local knee joint infection;
  • Have received systemic therapy before intervention or need to take systemic glucocorticoid therapy during the treatment;
  • Have a history of acute myocardial infarction or severe heart diseases,;
  • Subjects with peripheral or central nervous system disorders that may interfere assessments;
  • Have to Magnetic Resonance Imaging(MRI)
  • Subjects who are unable to walk on his own;
  • Subjects with alcohol/drug addiction/abuse or mental disorders;
  • Pregnant or lactating, or unable to comply with within 6 months after end of study;
  • Have participated in other clinical trials within 12 weeks before the screening;
  • Severe and poorly controlled comorbidities;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    NCR100 injection

    Subjects will receive four injections of NCR100

    Biological: NCR100

  • Placebo comparator
    0.9% Normal saline

    Subjects will receive four injections of 0.9% Normal saline

    Other: 0.9% Normal saline

  • Experimental
    NCR100 injection and 0.9% Normal saline

    Subjects will receive two injections of 0.9% Normal saline and two injections of NCR100

    Biological: NCR100 · Other: 0.9% Normal saline

Interventions

  • BiologicalNCR100

    Subjects will receive multiple intra-articular NCR100 injections.

  • Other0.9% Normal saline

    Subjects will receive multiple intra-articular 0.9% Normal saline injections.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity(DLT)

    Number of participants with Dose-limiting toxicity in 28 days

    Time frame: 4 weeks after first injection

  2. The Western Ontario and McMaster Universities osteoarthritis index(WOMAC)

    Differences of WOMAC scores in changes from baseline between the experimental group and the control group

    Time frame: 48 weeks after first injection

Secondary outcomes

  1. Adverse Event(AE) or Serious Adverse Event(SAE)

    Number of participants with treatment-related adverse events or serious adverse events assessed by CTCAE v5.0

    Time frame: Within 48 weeks of the first infusion

  2. Visual analogue scale (VAS)

    Differences in changes from baseline between experimental groups and the control group.

    Time frame: 8 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks

  3. Differences in changes from baseline at 8 weeks, 12 weeks, 24 weeks and 36 weeks of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) between the experimental groups and the control group

    WOMAC scores include three subscale scores (pain, stiffness, and physical function)

    Time frame: 8 weeks, 12 weeks, 24 weeks and 36 weeks

  4. Differences in changes from baseline to 24 weeks and 48 weeks in cartilages with various regions

    Magnetic resonance imaging (MRI) is used to scan images of knees.

    Time frame: 24 weeks and 48 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Nov 2026, 21 months later.

Of 39 phase 1/2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 18, 2024
StartEst.
Feb 20, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 15, 2028
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06741098
Lead sponsor
Nuwacell Biotechnologies Co., Ltd.
Collaborators
Shanghai 6th People's Hospital
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Feb 20, 2025 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 15, 2028 (estimated)
Last update
Dec 18, 2024

Study contacts

Yanqiu Li, PHD
Contact
yqli@nuwacell.com
021-64369181
Changqing 021-64369181, PHD
Contact
021-64369181

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NCR100

Start the discussion